Latest Ipo News

Anteris Technologies Global Corp. reported a $42.7 million net loss for the first half of 2025 amid advancing preparations for its pivotal DurAVR Transcatheter Heart Valve trial. The company’s recent IPO proceeds are fueling R&D and manufacturing scale-up as it targets regulatory approvals.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Vitrafy Life Sciences announces a leadership change with CEO Kate Munnings retiring and co-founder Brent Owens stepping up to lead the company’s next growth phase.

Lithium Energy Limited has made significant strides in its Capricorn Gold-Copper Belt and White Plains Lithium Brine projects, secured government funding, and received a major tranche payment from the Solaroz sale, while shelving its graphite IPO plans amid market challenges.

Advanced Health Intelligence Ltd has secured up to AUD 5.5 million from Oakley Capital Partners to support its ASX reinstatement and global expansion, while targeting an additional USD 6 million and unlocking $3 million in R&D grants.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Pure Hydrogen reports a second consecutive quarter of positive cash flow, expands its international hydrogen vehicle footprint, and secures a 15-year gas project permit in Queensland.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Lord Resources announces the resignation of CEO Andrew Taylor as exploration at the Ilgarari Copper Project advances under Georgina Clark’s management.

Robex Resources has successfully listed on the ASX, raising A$120 million to fund its Kiniéro Gold Project in Guinea, which remains on track for first gold production in late 2025. Meanwhile, steady output continues at its Nampala Mine in Mali despite rising costs.